SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the fin ...
News 13

NASA to retire moon rocket after Artemis III mission

KENNEDY SPACE CENTER — Citing the proposed budget cuts by the Trump administration, NASA announced on Friday that after the Artemis III mission — where Americans will return to the moon — the rocket ...
Barron's

SELLAS Life Sciences Group Inc.

About SELLAS Life Sciences Group Inc. SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for ...